At present no pharmacological inhibitors of CFLAR are routinely available, but second mitochondria-derived activator of caspase (SMAC)-mimetics, such as birinapant, have attracted attention as therapies in cancer, including myeloid malignancies. This evidence concerns the gene CFLAR and myeloid neoplasm.